We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Dyadic International Inc | NASDAQ:DYAI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.06 | -4.00% | 1.44 | 1.42 | 1.45 | 1.4999 | 1.40 | 1.48 | 8,546 | 16:06:38 |
Delaware
(State or other jurisdiction of incorporation or organization)
|
000-55264
(Commission File Number)
|
45-0486747
(I.R.S. Employer Identification Number)
|
140 Intracoastal Pointe Drive, Suite 404
Jupiter, FL 33477 |
||
(Address of principal executive offices and zip code)
|
||
(561) 743-8333
|
||
(Registrant’s telephone number, including area code)
|
||
N/A
(Former Name or Former Address, if Changed Since Last Report)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
|
Emerging growth company ☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
DYAI
|
The NASDAQ Stock Market LLC
|
●
|
general economic, political and market conditions;
|
●
|
our ability to generate the required productivity, stability, purity, performance, cost, safety and other data necessary to carry out and implement our biopharmaceutical research and business plans and strategic initiatives;
|
●
|
our ability to retain and attract employees, consultants, directors and advisors;
|
●
|
our ability to implement and successfully carry out Dyadic’s and third parties’ research and development efforts;
|
●
|
our ability to obtain new license and research agreements;
|
●
|
our ability to maintain our existing access to, and/or expand access to third party contract research organizations in order to carry out our research projects for ourselves and third parties;
|
●
|
competitive pressures and reliance on our key customers and collaborators;
|
●
|
the pharmaceutical and biotech industry, governmental regulatory and other agencies’ willingness to adopt, utilize and approve the use of the C1 gene expression platform;
|
●
|
the risk of theft, misappropriation or expiration of owned or licensed proprietary and intellectual property, genetic and biological materials owned by us and/or Danisco US, Inc. and VTT Technical Research Centre of Finland Ltd;
|
●
|
speculative nature and illiquidity of equity securities received as consideration from sub-licenses; and
|
●
|
the impact of the novel coronavirus identified as “COVID-19” on our business and operating results.
|
Item 9.01 Financial Statements and Exhibits
|
||
(d) Exhibits
|
||
The following exhibit is being furnished herein:
|
||
Exhibit
Number
|
Description
|
|
99.1
|
Dyadic International Presentation | |
104 | Cover page Interactive Data File (embedded within the Inline XBRL document) |
Dyadic International, Inc.
|
|
By:
|
/s/ Mark A. Emalfarb
|
Name:
|
Mark A. Emalfarb
|
Title:
|
Chief Executive Officer
|
1 Year Dyadic Chart |
1 Month Dyadic Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions